NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:

Balance sheets:

	December 31,
	2010		2011
a. Accounts receivable - other:
Deferred costs*			$	1,558
Institutions	$	634		375
State of Israel (see Note 6a )		878		1,296
Restricted deposit		226		208
Prepaid expenses		354		235
Sundry		139		165
	$	2,231	$	3,837
* Manufacturing costs of inventory, paid by Pfizer, but not delivered.

b. Accounts payable and accruals – other:

Payroll and related expenses	$	1,199	$	1,108
Provision for vacation and recreation pay		1,235		1,221
Accrued expenses		2,030		2,327
Royalties payable		884		89
Liability in connection with collaboration operation- current portion				1,322
Property and equipment supplier		2,720		1,473
	$	8,068	$	7,540

Statement of operations:

	Year ended December 31,
	2009		2010		2011

c. Revenues:
Deferred revenues from the license and supply agreement with Pfizer	$	388	$	4,563	$	4,563
Revenues from selling products to Pfizer				2,079		3,823
	$	388	$	6,642	$	8,386

d. Cost of Revenues:
Cost of products sold			$	807	$	985
Write down of inventories				2,692		363
Royalties expenses	$	3,575		884		177
	$	3,575	$	4,383	$	1,525

e. Research and development expenses - net:
Payroll and related expenses	$	10,479	$	13,176	$	14,042
Subcontractors and consultants		7,469		11,550		11,314
Materials and consumables		3,852		4,947		3,425
Rent, insurance and maintenance		2,238		3,457		4,113
Patent registration and licensing		387		571		449
Depreciation and write down		1,799		2,456		3,057
Other		1,166		1,534		1,418
		27,390		37,691		37,818
Less - grants and reimbursements:
Development costs reimbursements from Pfizer				3,922		3,430
Grants (see Note 6a)		5,752		3,818		3,345
	$	21,638	$	29,951	$	31,043
f. General and administrative expense:
Payroll and related expenses	$	2,804	$	2,415	$	2,481
Management and consulting fees		681		221		215
Rent, insurance and maintenance		347		463		498
Professional fees		2,274		2,274		2,326
Travel		251		308		229
Depreciation		191		309		363
Other		596		886		819
	$	7,144	$	6,876	$	6,931